Retatrutide reduces sleep apnea severity in OSA plus obesity
Healio · 12h ago
Untick a publication to hide it; your selections are stored in this browser. Journals, preprint servers, consumer brands and other high-volume feeds are off by default.
Medicine & Biotech · covered by 10 outlets this week · tracked since 2026-10-27
Press: 6 mainstream 16 specialist 7 independent outlet-days
Retatrutide is an experimental drug for obesity developed by the American pharmaceutical company Eli Lilly and Company. It is a triple hormone receptor agonist on the GLP-1, GIP, and glucagon receptors. Wikipedia ↗
Written by the Alivewire editors from the coverage below, 19h ago. Not medical advice; how the ratings work.